Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 6/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549613 | 0.84 | CYP2C19 (0.70) | MAPTLMNAPOLBTP53CYP2C19 | |
| SCHEMBL17545311 | 0.82 | CYP2C19 (0.77) | MAPTLMNAPOLBTP53CYP2C19 | |
| SCHEMBL17545356 | 0.82 | ACLY (0.60) | MAPTLMNAPOLBTP53ALDH1A1 | |
| SCHEMBL17545248 | 0.79 | TP53 (0.67) | MAPTLMNAPOLBTP53CYP2C19 | |
| SCHEMBL17545068 | 0.77 | NPC1 (0.64) | MAPTLMNAPOLBTP53CYP2C19 | |
| SCHEMBL17492500 | 0.75 | NPSR1 (0.68) | MAPTLMNAPOLBTP53CYP2C19 | |
| SCHEMBL21469216 | 0.74 | LMNA (0.66) | LMNAPOLBTP53CYP2C19ALDH1A1 | |
| SCHEMBL21469259 | 0.72 | TSHR (0.68) | MAPTLMNAPOLBTP53CYP2C19 | |
| SCHEMBL21469255 | 0.72 | MAPT (0.51) | MAPTLMNAPOLBTP53GAA | |
| SCHEMBL21469285 | 0.72 | POLB (0.55) | MAPTLMNAPOLBTP53CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021469-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190337931-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO | 2019-11-07 | — | — | US | disclosed |
| EP-3180312-B1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | UNIV LOYOLA CHICAGO (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | MAPT 2069/4885LMNA 3262/4885POLB 1517/4885 |
| US-20190337931-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | MAPT 2069/4885LMNA 3262/4885POLB 1517/4885 |
| US-11021469-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | MAPT 2069/4885LMNA 3262/4885POLB 1517/4885 |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | MAPT 2069/4885LMNA 3262/4885POLB 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.